Covid and Omicron vaccine, Modern towards bivalent booster in autumn

Moderna is evaluating a bivalent anti-Covid booster vaccine (mRna-1273.214) that combines the currently licensed vaccine also as a booster with a booster candidate specific for Omicron variants. Initial results of the study, clinical phase 2-3, are expected in the second quarter of the year and this bivalent product “remains our main candidate for a booster dose” to be administered “in the Northern Hemisphere in the fall of 2022”, explains the CEO of the American company, St├ęphane Bancel. “We look forward to sharing initial data on mRna-1273.214 in the second quarter – adds the CEO – We believe that a bivalent booster vaccine, if authorized, would represent a new tool” to protect against Covid-19, “while we continue to respond to emerging variants “of the SARS-CoV-2 coronavirus.